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Abstract
Plasmid-mediated AmpC b-lactamase-producing Escherichia coli (AmpC-E) bacteraemia was characterized by comparison with bactera-
emia caused by extended-spectrum b-lactamase (ESBL)-producing E. coli (ESBL-E) and non-resistant E. coli (NR-E) in the era of the
worldwide spread of the CTX-M-15-producing O25b-ST131-B2 clone. Of 706 bloodstream E. coli isolates collected between 2005 and
2010 in three Japanese university hospitals, 111 ESBL screening-positive isolates were analysed for AmpC and ESBL genes by PCR. A
case–control study was performed in which the cases consisted of all of the patients with AmpC-E bacteraemia. Phylogenetic groups,
sequence types and O25b serotype were determined. Twenty-seven AmpC-E isolates (26 of which were of the CMY-2 type) were
identiﬁed, and 54 ESBL-E and 54 NR-E isolates were selected for the controls. Nineteen AmpC-E isolates were also positive for ESBL.
CTX-M-14 was the most prevalent ESBL type among both the AmpC-E and ESBL-E isolates. The O25b-ST131-B2 clone was the most
prevalent among the ESBL-E isolates (26%) and the second most prevalent among the NR-E isolates (13%), but only one O25b-ST131-
B2 clone was found among the AmpC-E isolates. Twenty-three different sequence types were identiﬁed among the AmpC-E isolates.
When compared with bacteraemia with ESBL-E, previous isolation of multidrug-resistant bacteria and intravascular catheterization were
independently associated with a lower risk for AmpC-E. When compared with NR-E bacteraemia, prior use of antibiotics was the only
signiﬁcant risk factor for AmpC-E. Unlike the spread of the O25b-ST131-B2 clone between ESBL-E and NR-E, the AmpC-E isolates
were not dominated by any speciﬁc clone.
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Introduction
Bacteraemia caused by Escherichia coli is a common and signif-
icant problem in both community and healthcare-associated
settings [1]. In recent years, the prevalence of extended-
spectrum b-lactamase (ESBL)-producing E. coli has increased
dramatically worldwide [2]. A CTX-M-15 ESBL-producing
E. coli (ESBL-E) isolate with sequence type (ST)131, belonging
to the O25b serogroup and the B2 phylogenetic group, has
emerged as a pandemic clone [3].
The prevalence of plasmid-mediated AmpC b-lactamase
(pAmpC)-producing E. coli isolates that also gain resistance
to broad-spectrum cephalosporins has likewise been increas-
ing [4]. The ESBL screening and conﬁrmation tests described
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by the CLSI are useful for identifying ESBL-E [5]. Although
pAmpC-producing E. coli (AmpC-E) are positive by CLSI
ESBL screening tests and are generally negative by the CLSI
ESBL conﬁrmation test, standard guidelines for detecting
pAmpC remain unavailable [6]. Therefore, AmpC-E cannot
be identiﬁed in routine laboratory practice.
Many reports have shown the microbiological characteris-
tics, risk factors or prognosis of infections caused by ESBL-E
[5]. However, information on the characteristics of AmpC-E,
particularly with regard to clinical data, is limited. In this
study, we describe the microbiological and clinical character-
istics of AmpC-E recovered from blood cultures through
comparison with ESBL-E and non-resistant E. coli (NR-E).
Materials and Methods
Setting and study design
This study was conducted at three tertiary-care university hos-
pitals in Japan: Kyoto University Hospital, Kyoto Prefectural
Medical University Hospital, and Nagoya University Hospital.
All of the bacteraemia episodes in our hospitals were reported
to and followed up by our infectious disease physicians.
Changes in antimicrobial treatment and general management
were advised if considered necessary. All of the patients with
bacteraemia caused by E. coli that occurred between January
2005 and December 2010 were enrolled in this study. Each
patient was included in the study only once, at the time of the
initial positive blood culture. A case–control–control study
design was used. The case group was composed of all of the
patients with AmpC-E bacteraemia, irrespective of the pres-
ence of the ESBL genes. The ﬁrst control group consisted of
patients with ESBL-E bacteraemia, and the second consisted of
patients with NR-E bacteraemia. The NR-E patients were
selected from the patients with ESBL screening-negative iso-
lates. The case patients were matched in a 1 : 2 ratio with the
ESBL-E and NR-E control patients. The matching of ESBL-E
and NR-E patients was based on the hospital and the closest
date to the isolation of the AmpC-E. The Ethics Committee of
each hospital approved this study and waived the need to
obtain informed consent from each patient.
Variables and deﬁnitions
The bacteraemias were categorized as nosocomial, health-
care-associated, or community-acquired, in accordance with
the criteria of Friedman et al. [7]. Neutropenia was deﬁned
as an absolute neutrophil count below 500/mm3. Multidrug-
resistant (MDR) bacteria included ESBL producers, metallo-
b-lactamase producers (detected with mercaptoacetic acid),
multidrug (imipenem, amikacin, and ciproﬂoxacin)-resistant
Pseudomonas aeruginosa, methicillin-resistant Staphylococcus
aureus, and vancomycin-resistant enterococci. The empirical
therapy was considered to be appropriate if an active antimi-
crobial agent determined by in vitro susceptibility testing was
administered at the usual recommended dose during the ﬁrst
24 h after the blood sample was obtained.
The clinical information acquired from the medical charts
included age, sex, the length of the hospital stay before bac-
teraemia, history of MDR bacterial isolation, receipt of
immunosuppressive therapy during the previous 30 days, any
antimicrobial therapy during the previous 90 days, underlying
diseases, surgery during the previous 30 days, neutropenia,
the presence of an intravenous catheter or any other artiﬁ-
cial device, the site of infection, the SOFA score [8], the
presence of severe sepsis or septic shock at the time of
blood culture collection, intensive-care unit admission, and
the antimicrobial regimen.
The main outcome measure was the 30-day mortality
rate. Additionally, the time to response to treatment was
assessed every 24 h after the start of antimicrobial therapy,
and complete response was deﬁned as resolution of fever,
leukocytosis, and all signs of infection.
Microbiological analysis
In each hospital, microbiological identiﬁcation was deter-
mined with the Vitek2 (bioMe´rieux, Marcy l’Etoile, France)
or MicroScan (Siemens Healthcare Diagnostics, Tokyo, Japan)
system. The ESBL screening was performed according to the
CLSI microdilution methodology, with modiﬁcations (cefo-
taxime, ‡8 mg/L; ceftazidime, ‡2 mg/L; or aztreonam, ‡8 mg/
L) [9]. Conﬁrmation of ESBL production was performed with
the double-disk synergy test, following the CLSI guidelines.
All of the ESBL screening-positive isolates and NR-E iso-
lates were sent to a reference laboratory (Kyoto University
Hospital). These isolates were subjected to PCR ampliﬁca-
tion of the blaSHV, blaTEM, blaOXA-1 [10] and blaCTX-M genes
[11] and of the six main groups of pAmpC-type genes [12].
The amplicons of the pAmpC-type and blaCTX-M genes were
directly sequenced. For the blaSHV-positive and blaTEM-posi-
tive isolates, the entire gene was sequenced [13,14]. All of
the isolates included in the study were further characterized
by their plasmid-mediated quinolone resistance (PMQR)
determinants (qnrA, qnrB, qnrC, qnrS, and aac(6¢)-Ib-cr) [15],
phylogenetic groups by using triplex PCR (A, B1, B2, and D)
[16], serogroup O25b rfb PCR [17], multilocus sequence typ-
ing (MLST) according to the E. coli MLST website (http://
mlst.ucc.ie/mlst/dbs/Ecoli), and random ampliﬁed polymorphic
DNA (RAPD) ﬁngerprinting with a DAF4 primer [18], as
previously described. Among the novel STs found in this
study, the single-locus variants of the previously known ST
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complexes were considered to belong to the previously
identiﬁed ST complexes. The isolates with identical RAPD
patterns were subjected to pulsed-ﬁeld gel electrophoresis
analysis with the SpeI endonucluease. The digitized gel images
were subjected to analysis with GelCompar II, version 4.6
(Applied Maths, Sint-Martens-Latem, Belgium). The antibiotic
susceptibility was evaluated by microdilution, and categorized
according to the 2010 revised CLSI breakpoints [9].
Statistical analysis
The categorical variables were compared by use of Fisher’s
exact test. The continuous variables were compared by use
of the Mann–Whitney U-test. To determine the independent
risk factors for AmpC-E bacteraemia, all variables with a p-
value of <0.10 based on univariate analyses were subjected
to further selection by using a forward stepwise logistic pro-
cedure. A p-value of <0.05 was considered to be statistically
signiﬁcant. We conducted our statistical analysis with Stata,
version 11.2 (StataCorp, College Station, TX, USA).
Results
During the study period, a total of 706 E. coli isolates were
recovered from patient blood. Of those, 111 (16%) were posi-
tive for ESBL screening. The PCR analysis identiﬁed 27 AmpC-
E and 98 ESBL-E isolates, 19 of which were positive for both
the pAmpC and the ESBL genes (Table 1). The remaining ﬁve
isolates harboured neither pAmpC nor ESBL. Only ﬁve of the
19 AmpC-E isolates with the ESBL gene were positive by the
ESBL conﬁrmation test. In our analysis, the cases consisted of
the 27 patients with AmpC-E bacteraemia, and the 54 patients
with ESBL-E bacteraemia and the 54 patients with NR-E bac-
teraemia were matched comparisons.
Microbiological results
The antibiotic susceptibilities are shown in Table 2. All of
the isolates in this study were susceptible to imipenem
TABLE 1. The extended-spectrum b-lactamase (ESBL) con-
ﬁrmation test and the presence of the ESBL gene among
the Escherichia coli isolates with positive ESBL screening
test results from blood
ESBL gene
ESBL conﬁrmation testa
Positive
(n = 98)
Negative
(n = 13)
Positive 81 (5) 3 (0)
Negative 17 (14) 10 (8)
The number of pAmpC gene-positive isolates is presented in parentheses.
aThe double-disk synergy test was performed according to the CLSI guidelines. T
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(MIC £1 mg/L). The susceptibility rates among the AmpC-E
isolates were similar, irrespective of ESBL co-production.
The co-resistance rates for non-b-lactam antimicrobials were
similar between the AmpC-E and NR-E isolates, but signiﬁ-
cantly higher resistance to ciproﬂoxacin was observed in the
ESBL-E than in the AmpC-E isolates. Table 3 shows the
resistance genes for each group of isolates. CMY-2 was the
most common pAmpC type. CTX-M-14, which belongs to
the CTX-M-9 group, was the most common ESBL in both
the AmpC-E with ESBL and ESBL-E groups. PMQR determi-
nants were rarely found in any of the three groups.
Table 4 shows that the MLST analysis identiﬁed 23 differ-
ent STs (including seven novel STs) in the AmpC-E isolates,
19 different STs (including one novel ST) in the ESBL-E iso-
lates, and 27 different STs (including seven novel STs) in the
NR-E isolates. Among the ESBL-E isolates, ST131-B2 was the
most prevalent (n = 14, 26%), followed by ST405-D (n = 10,
19%). ST131-B2 was also prevalent (n = 9, 17%) among the
NR-E isolates, but STC95-B2 was the most prevalent
(n = 13, 24%). A single ST131-B2 isolate was found among
the AmpC-E isolates with ESBL. Multiple AmpC-E isolates
were found in ST95, STC155, and ST38, all of which were
distributed irrespective of ESBL co-production.
Of 24 ST131-B2 isolates identiﬁed in this study, 22 were
positive for O25b detection, except for two NR-E isolates;
the susceptibility rates for ciproﬂoxacin, gentamicin and tri-
methoprim–sulphamethoxazole were 8%, 64%, and 36%,
respectively. CTX-M-27 (n = 6) was the most common ESBL
type, followed by CTX-M-2 (n = 3), CTX-M-14 (n = 3),
CTX-M-3 (n = 1), CTX-M-15 (n = 1), and CTX-M-24
(n = 1). One isolate with blaCTX-M-14 also had blaCMY-2. The
TEM-1 gene was found in 14 isolates. PMQR determinants
and blaOXA-1 were not found.
Twenty-six AmpC-E, 51 ESBL-E and 52 NR-E isolates had
distinguishable patterns by RAPD analysis. Three clusters
(each with two isolates) were subjected to pulsed-ﬁeld gel
electrophoresis analysis. Two clusters showed distinguishable
patterns. The other cluster, which was composed of two
NR-E isolates, showed an indistinguishable pattern.
Clinical features
Table 5 lists the risk factors and outcomes for bacteraemia
with the AmpC-E isolates. A shorter hospital stay, less fre-
quent previous isolation of MDR bacteria and a reduced fre-
quency of intravascular catetherization were observed in
cases of AmpC-E bacteraemia with or without ESBL than for
ESBL-E, although not all of the variables reached statistical
signiﬁcance. Multivariate analysis was performed only for all
of the AmpC-E patients, owing to the small number of
patients with AmpC-E bacteraemia with or without ESBL;
patients with previous isolation of MDR bacteria (OR 0.19,
CI 0.04–0.92) and intravascular catheterization (OR 0.32,
CI 0.12–0.86) were at lower risk for AmpC-E bacteraemia.
When compared with NR-E, prior use of antibiotics was the
only signiﬁcant risk factor for AmpC-E bacteraemia with
ESBL or AmpC-E bacteraemia as a whole, and intravascular
catheterization was associated with a lower risk for AmpC-E
bacteraemia without ESBL. Multivariate analysis was not per-
TABLE 3. The resistance genes of
the plasmid-mediated AmpC b-lac-
tamase (pAmpC)-producing Escher-
ichia coli isolates as compared with
those of the extended-spectrum b-
lactamase (ESBL)-producing E. coli
and non-resistant E. coli isolates
Characteristics
pAmpC only
(n = 8),
no. (%)
pAmpC + ESBL
(n = 19),
no. (%)
ESBL
(n = 54),
no. (%)
No resistance
(n = 54),
no. (%)
pAmpC-type b-lactamase
CMY-2 8 (100) 18a (95) 0 (0) 0 (0)
CMY-10 0 (0) 1 (5) 0 (0) 0 (0)
DHA-1 0 (0) 1 (5) 0 (0) 0 (0)
ESBL-type b-lactamase
CTX-M 0 (0) 19b (100) 51 (94) 0 (0)
CTX-M-14 0 (0) 17c (89) 26d (48) 0 (0)
CTX-M-15 0 (0) 2 (11) 7e (13) 0 (0)
CTX-M-2 0 (0) 1 (5) 8 (15) 0 (0)
CTX-M-27 0 (0) 1 (5) 6 (11) 0 (0)
CTX-M-3 0 (0) 0 (0) 4 (7) 0 (0)
CTX-M-24 0 (0) 0 (0) 1 (2) 0 (0)
TEM-20 0 (0) 0 (0) 2 (4) 0 (0)
SHV-12 0 (0) 0 (0) 3 (6) 0 (0)
Other resistance genes
TEM-1 3 (38) 3 (16) 21 (39) 20 (37)
OXA-1 1 (13) 0 (0) 1 (2) 0 (0)
qnrf 0 (0) 2 (11) 1 (2) 2 (4)
aac(6¢)-Ib-cr 1 (5) 1 (5) 3 (6) 0 (0)
aOne isolate was positive for DHA-1 and CMY-2.
bAll of the isolates with the CTX-M designation were positive for CMY-2.
cTwo isolates were positive for CTX-M-14 and CTX-M-15.
dOne isolate was positive for CTX-M-14, CTX-M-15, and SHV-12.
eOne isolate was positive for CTX-M-15 and SHV-12.
fqnrB4 and qnrS1 were found in the pAmpC + ESBL group, qnrB19 was found in the ESBL group, and qnrB19 and
qnrS1 were found in the non-resistant group.
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formed. The 30-day mortality among the patients with
AmpC-E bacteraemia with ESBL (11%) was increased as
compared with patients with AmpC-E bacteraemia without
ESBL (0%), but was reduced as compared with patients with
ESBL-E bacteraemia (22%), although not signiﬁcantly.
Discussion
Among the 705 E. coli isolates obtained from blood during
the study period, 27 (3.8%) were AmpC-E. Nineteen of
these AmpC-E isolates were also positive for ESBL, which
contributed to the low sensitivity (83%) of the ESBL conﬁr-
mation test. This low sensitivity can endanger patients when
the old (prior to 2010) CLSI breakpoints are used, as false
susceptibility to cephalosporins can be reported.
The CTX-M type, which is associated with the interna-
tional emergence of the O25b-ST131-B2 clone, is now
spreading worldwide [2]. CTX-M-15 (CTX-M-1 group) is
most closely associated with the O25b-ST131-B2 clone, and
is thus the most widely distributed CTX-M subtype. The plas-
mids of ST131 frequently carry both CTX-M-15 and TEM-1,
OXA-1, and aac(6¢)-Ib-cr [3]. Apart from ESBL producers,
ST131 has been frequently found in ﬂuoroquinolone-resistant
isolates but infrequently found in non-resistant isolates [3]. In
our study, O25b-ST131-B2 was the most prevalent clone
among the ESBL-E infections. This clone was characterized by
ESBL of the CTX-M-9 group (CTX-M-27, CTX-M-14, and
CTX-M-24), TEM-1, and resistance to ciproﬂoxacin. The dif-
ference in the prevalence of the CTX-M type has been previ-
ously observed in a nationwide Japanese study [19]. O25b-
ST131 with CTX-M-14 and ST38 with CTX-M-9 have been
reported to be the two dominant clones among ESBL-E iso-
lates [19]. Although many studies have investigated the distri-
bution of STs, the data from bloodstream isolates are limited.
To date, Pitout et al. have conducted the largest MLST analy-
sis, using 67 ESBL-E bacteraemia isolates and ﬁnding 21
ST131 isolates [20]. An MLST analysis of bacteraemia caused
by NR-E without ciproﬂoxacin resistance has not yet been
investigated. We found that the O25b-ST131-B2 clone with
ciproﬂoxacin resistance was the second most prevalent
among NR-E isolates. Like ST131, CTX-M-15-producing
ST405 has been detected worldwide [21]. The ST405-D iso-
lates were the second most prevalent among our ESBL-E iso-
lates. The ciproﬂoxacin-resistant ST393-D and trimethoprim–
sulphamethoxazole-resistant ST69-D are similarly known to
be distributed globally [22]. Although we did identify these
clones among the ESBL-E and NR-E isolates, they were not
prevalent. Surveillance in Spain has found that STC10, STC23
and ST131 are common among infections caused by ESBL-E,
half of which produced CTX-M-14 [23]. These reported ST
distributions are consistent with our results.
CMY-2 is the most common pAmpC type in the world,
including Japan [4,24]. There have been four studies analysing
TABLE 4. The distribution of sequence types and phylogenetic groups among the plasmid-mediated AmpC b-lactamase
(pAmpC)-producing, extended-spectrum b-lactamase (ESBL)-producing and non-resistant Escherichia coli isolates
STC
STa (phylogenetic group)
pAmpC only (n = 8) pAmpC + ESBL (n = 19) ESBL (n = 54) No resistance (n = 54)
STC95 951 (D) 952 (B2) 954 (B2) 9512 (B2), 22671 (B2)
STC405 40510 (D) 4051 (D)
STC73 731 (B2) 734 (B2), 22701 (D)
STC69 691 (D) 691 (D) 693 (D)
STC23 233 (A) 22641 (A)
STC31 3932 (D) 3932 (D)
STC38 381 (D) 381 (D) 382 (D)
STC155 581 (B1), 21701 (B1) 1551 (B1) 581 (B1)
STC446 6024 (B1)
STC10 101 (A), 1671 (A) 22661 (A)
STC354 3543 (D)
STC12 121 (B2)
STC14 5501 (B2)
STC156 1561 (B1)
STC168 931 (B2)
STC349 3491 (B2)
STC350 571 (D)
STC469 22651 (B1)
STC538 5381 (B2)
Singletons 2241(B1), 6571 (D) 702 (D), 1151 (D), 1311 (B2), 3621 (D),
4201(D), 14851 (D), 21711 (D), 21721
(B1), 21731 (B2), 21751 (B1), 21761
(B1), 21771 (A)
13114 (B2), 22162 (D), 1171 (D),
5011 (D), 6481 (D), 10921 (B2)
1319 (B2), 1272 (B2), 3622 (D), 1261 (B2),
2951 (B1), 2971 (B1), 3451 (B1), 3571 (B2),
9421 (B2), 9981 (B2), 14061 (D), 16291 (D),
22681 (B2), 23061 (B1)
ST, sequence type; STC, ST complex.
Among the novel STs found in this study (ST2170–ST2177, ST2216, ST2264–ST2268, ST2270, and ST2306), the single-locus variants of previously known STCs were consid-
ered to belong to their STCs. ST2268 is the single-locus variant of ST131.
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STs among AmpC-E isolates (mostly consisting of the CMY-2
group) from clinical samples [25–28]. The prevalence of
ST131 among AmpC-E isolates has been reported to be
lower than 10%, and AmpC-E isolates co-producing ESBL are
rare. Here, we identiﬁed only one ST131 among our AmpC-
E isolates with ESBL, although ESBL co-producers consisted
of two-thirds of the AmpC-E isolates. Studies in Denmark
[26] and Spain [28] have reported a variety of STs, whereas
studies in France [25] and Norway [27] have reported the
existence of small clusters of speciﬁc clones (STC38 and
STC448 in Norway, and STC156 and STC46 in France). Our
AmpC-E isolates were not conﬁned to any speciﬁc cluster,
and 26% were of a previously unreported ST. These four
studies reported that the phylogenetic groups D and B1
were the most prevalent types. Even in the situation of a
high prevalence of ESBL co-producers, these results are con-
sistent with ours, and suggest that the spread of AmpC-E is
different from that of ESBL-E, in which a speciﬁc, virulent
O25b-ST131-B2 clone plays an important role.
Previous antimicrobial use and association with the health-
care environment were reported to be the risk factors for
CMY-2-producing E. coli bacteraemia as compared with NR-E
bacteraemia [29]. In our study, previous antimicrobial use
was the only signiﬁcant risk factor for AmpC-E bacteraemia
with ESBL or AmpC-E bacteraemia. To the best of our
knowledge, no study has compared the clinical features of
TABLE 5. The clinical characteristics of the case patients with bacteraemia caused by plasmid-mediated AmpC b-lactamase
(pAmpC)-producing Escherichia coli as compared with those of the patients with bacteraemia caused by extended-spectrum b-
lactamase (ESBL)-producing E. coli and the patients with bacteraemia caused by non-resistant E. coli
p-value
pAmpC pAmpC vs. pAmpC only vs. pAmpC + ESBL vs.
Characteristics
Total
(n = 27)
pAmpC
onlya (n = 8)
pAmpC
+ ESBLa
(n = 19)
ESBL
(n = 54)
No
resistance
(n = 54) ESBL
No
resistance ESBL
No
resistance ESBL
No
resistance
Age (years) 67 (56–77) 75 (63.5–77.5) 65 (44–75) 66 (58–75) 69 (63.5–75) 0.73 0.21 0.27 0.48 0.24 0.25
Male sex 15 (56) 3 (38) 12 (63) 37 (69) 31 (57) 0.33 1 0.12 0.45 0.78 0.79
Nosocomial or healthcare-
associated bacteraemia
18 (67) 5 (63) 13 (68) 46 (85) 31 (57) 0.08 0.48 0.14 1 0.17 0.43
Length of hospital stay
before bacteraemia (days)
1 (0–21) 0.5 (0–2) 3 (0–31) 22 (3–49) 6 (0–25) 0.003 0.51 0.004 0.20 0.04 0.94
Previous isolation of MDR
bacteria
2 (7) 1 (13) 1 (5) 16 (30) 7 (13) 0.03 0.71 0.43 1 0.03 0.67
Previous antimicrobial use 17 (63) 4 (50) 13 (68) 39 (72) 20 (37) 0.45 0.04 0.24 0.70 0.78 0.03
Use of immunosuppressive
drugs
6 (22) 2 (25) 4 (21) 16 (30) 7 (13) 0.60 0.34 1 0.33 0.56 0.46
Haematological malignancy 2 (7) 0 (0) 2 (11) 12 (22) 5 (9) 0.13 1 0.34 1 0.33 1
Solid malignancy 9 (33) 3 (38) 6 (32) 19 (35) 22 (41) 1 0.63 1 1 1 0.59
Transplantation 2 (7) 1 (13) 1 (5) 10 (19) 2 (4) 0.32 0.60 1 0.34 0.27 1
Haemodialysis 1 (4) 0 (0) 1 (5) 6 (11) 1 (2) 0.42 1 1 1 0.67 0.46
Diabetes 5 (19) 3 (38) 2 (11) 5 (9) 11 (20) 0.29 1 0.06 0.37 1 0.49
Surgery 3 (11) 0 (0) 3 (16) 5 (9) 6 (11) 1 1 1 1 0.42 0.69
Neutropenia 3 (11) 0 (0) 3 (16) 15 (28) 5 (9) 0.16 1 0.18 1 0.37 0.42
Intravascular catheterization 10 (37) 0 (0) 10 (53) 35 (65) 21 (39) 0.03 1 0.001 0.04 0.42 0.42
Artiﬁcial devices other than
intravascular catheter
6 (22) 2 (25) 4 (21) 18 (33) 9 (17) 0.44 0.56 1 0.62 0.39 0.73
Site of infection
Intra-abdominal infection 12 (44) 3 (38) 9 (47) 14 (26) 14 (26) 0.13 0.13 0.67 0.67 0.10 0.10
Urinary tract 8 (30) 3 (38) 5 (26) 18 (33) 29 (54) 0.81 0.06 1 0.47 0.78 0.06
Primary 6 (22) 2 (25) 4 (21) 17 (31) 10 (19) 0.44 0.77 1 0.65 0.56 1
Others 1 (4) 0 (0) 1 (5) 5 (9) 1 (2) 0.66 1 1 1 1 0.46
Severity
SOFA score 2 (0–6) 1 (0–5.5) 3 (1–6) 3.5 (1.75–7) 2 (0–4.25) 0.25 0.27 0.23 0.93 0.48 0.15
Severe sepsis or septic
shock
10 (37) 3 (38) 7 (37) 23 (43) 12 (22) 0.81 0.19 1 0.39 0.79 0.24
ICU admission 2 (7) 0 (0) 2 (11) 9 (17) 1 (2) 0.32 0.26 0.59 1 0.72 0.16
Appropriate empirical
therapy
21 (78) 6 (75) 15 (79) 41 (76) 53 (98) 1 0.005 1 0.04 1 0.02
Complete response
within 72 h
11 (41) 5 (63) 6 (32) 15 (28) 25 (46) 0.31 0.81 0.10 0.47 0.77 0.30
Complete response
within 7 days
19 (70) 7 (88) 12 (63) 33 (61) 49 (91) 0.47 0.03 0.24 0.58 1 0.01
30-day mortality 2 (7) 0 (0) 2 (11) 12 (22) 3 (6) 0.13 1 0.34 1 0.33 0.60
ICU, intensive-care unit; MDR, multidrug-resistant; SOFA, sequential organ failure assessment.
The data are presented as the number (%) or median (interquartile range).
aThe clinical characteristics were not signiﬁcantly different between the pAmpC-only group and the pAmpC with ESBL group, except for intravascular catheterization
(p 0.01).
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AmpC-E bacteraemia with those of ESBL-E bacteraemia. A
similar comparison between ﬁve CMY-2-producing and 14
chromosomal AmpC b-lactamase-producing E. coli bacterae-
mias with 19 ESBL-E bacteraemias was conducted, and
immunosuppression and prior antimicrobial use caused a
lower risk for AmpC b-lactamase producers [30]. We simi-
larly found a lower association with the healthcare environ-
ment for AmpC-E than for ESBL-E.
The limitations of the present study included a relatively
small number of AmpC-E isolates, especially pAmpC-only
isolates, which limited the power of our statistical analysis.
However, the antibiotic susceptibilities, the ST distribution
and the clinical characteristics of AmpC-E isolates were
similar between ESBL and non-ESBL producers, but were
different from those of ESBL-E isolates. Furthermore, it is
difﬁcult to distinguish ESBL producers from AmpC-E with
routine phenotypic tests, including an ESBL conﬁrmation
test.
In conclusion, AmpC-E with or without ESBL have differ-
ent characteristics from ESBL-E, although both are resistant
to extended-spectrum cephalosporins and are important
causes of E. coli bacteraemia. One-half of the ESBL-E infec-
tions were caused by ciproﬂoxacin-resistant O25b-ST131-B2
and ST405-D clones, and one half of the NR-E infections
were caused by ciproﬂoxacin-resistant O25b-ST131-B2 and
STC95-B2 clones. Among the AmpC-E infections, however, a
speciﬁc dominant clone was not observed, although two-
thirds of AmpC-E isolates harboured the CTX-M-14-type
ESBL gene. The clinical analysis showed that antimicrobial
use increased the risk for AmpC-E, but there was also less
association between AmpC-E and healthcare settings than
for ESBL-E. Considering the close relationship between the
emergence of the ST131 clone and the spread of ESBL-E,
further monitoring and clinical data are required to control
the spread of drug-resistant E. coli.
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